- Home
- CRIS vs BIVI Comparison
CRIS vs BIVI Comparison
Compare CRIS & BIVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRIS
- BIVI
- Stock Information
- Founded
- CRIS 2000
- BIVI 2013
- Country
- CRIS United States
- BIVI United States
- Employees
- CRIS N/A
- BIVI N/A
- Industry
- CRIS Biotechnology: Biological Products (No Diagnostic Substances)
- BIVI Biotechnology: Pharmaceutical Preparations
- Sector
- CRIS Health Care
- BIVI Health Care
- Exchange
- CRIS Nasdaq
- BIVI Nasdaq
- Market Cap
- CRIS 21.3M
- BIVI 18.6M
- IPO Year
- CRIS 2000
- BIVI N/A
- Fundamental
- Price
- CRIS $2.37
- BIVI $1.08
- Analyst Decision
- CRIS Strong Buy
- BIVI Strong Buy
- Analyst Count
- CRIS 2
- BIVI 1
- Target Price
- CRIS $16.50
- BIVI $30.00
- AVG Volume (30 Days)
- CRIS 76.2K
- BIVI 282.1K
- Earning Date
- CRIS 07-31-2025
- BIVI 05-12-2025
- Dividend Yield
- CRIS N/A
- BIVI N/A
- EPS Growth
- CRIS N/A
- BIVI N/A
- EPS
- CRIS N/A
- BIVI N/A
- Revenue
- CRIS $11,202,000.00
- BIVI N/A
- Revenue This Year
- CRIS $0.93
- BIVI N/A
- Revenue Next Year
- CRIS $8.10
- BIVI N/A
- P/E Ratio
- CRIS N/A
- BIVI N/A
- Revenue Growth
- CRIS 14.17
- BIVI N/A
- 52 Week Low
- CRIS $1.02
- BIVI $0.62
- 52 Week High
- CRIS $9.72
- BIVI $7.50
- Technical
- Relative Strength Index (RSI)
- CRIS 59.94
- BIVI 53.42
- Support Level
- CRIS $2.23
- BIVI $1.07
- Resistance Level
- CRIS $2.63
- BIVI $1.13
- Average True Range (ATR)
- CRIS 0.18
- BIVI 0.06
- MACD
- CRIS 0.03
- BIVI 0.00
- Stochastic Oscillator
- CRIS 67.09
- BIVI 65.99
About CRIS Curis Inc.
Curis Inc is a biotechnology company that develops and commercializes drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.
About BIVI BioVie Inc.
BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The Company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.